Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma

More effective treatments are needed for low-grade serous ovarian carcinoma (LGSOC). Our patient, who suffers from metastatic LGSOC, had received all established treatments. Sequencing analysis revealed an activating BRAF mutation. Therefore, combined treatment with BRAF and MEK inhibitors, which is...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: Bengt Tholander, Anthoula Koliadi, Johan Botling, Hanna Dahlstrand, Anne Von Heideman, Håkan Ahlström, Kjell Öberg, Gustav J. Ullenhag
Formáid: Alt
Teanga:English
Foilsithe / Cruthaithe: Upsala Medical Society 2020-10-01
Sraith:Upsala Journal of Medical Sciences
Ábhair:
braf inhibitor
chemotherapy
low-grade serous ovarian cancer
mek inhibitor
next-generation sequencing
surgery
targeted therapy
v600e mutation
Rochtain ar líne:http://dx.doi.org/10.1080/03009734.2020.1826612

Ar líne

http://dx.doi.org/10.1080/03009734.2020.1826612

Míreanna comhchosúla